OpSens Announces FDA Clearance for the SavvyWire™ for Use in Transcatheter Aortic Valve Replacement (TAVR) Procedures
15 September 2022OpSens Announces FDA Clearance for the SavvyWire™ for Use in Transcatheter Aortic Valve Replacement (TAVR) Procedures Quebec City, Quebec, September 15, 2022 – OpSens Inc. (“OpSens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF), a medical device cardiology-focused company delivering innovative solutions based on its proprietary optical technology, today announced that it has received 510(k) regulatory clearance from…
Opsens Solutions will be present at ESREF 2022, in Berlin (Germany) from September 26-29, 2022
9 September 2022Opsens Solutions will be present at ESREF 2022, in Berlin (Germany) from September 26-29, 2022 at the H4 Hotel Berlin Alexanderplatz, Please come to visit us at booth 2.